GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » NonCurrent Deferred Liabilities

Alto Neuroscience (Alto Neuroscience) NonCurrent Deferred Liabilities : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Alto Neuroscience's non-current deferred liabilities for the quarter that ended in Mar. 2024 was $0.00 Mil.

Alto Neuroscience NonCurrent Deferred Liabilities Historical Data

The historical data trend for Alto Neuroscience's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience NonCurrent Deferred Liabilities Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
- - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial - - - - -

Alto Neuroscience NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience (Alto Neuroscience) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus